Capricor Therapeutics To Present One-Year Efficacy Results From Its Ongoing HOPE-2 Open Label Extension Study At 2022 Parent Project Muscular Dystrophy Annual Conference [TheStreet.com]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: TheStreet.com
of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year's. The details are as follows: Dr. Linda Marbán, CEO, will present the one-year open label extension results via a late-breaking session on June 25, 2022, at 5:05 p.m. MT. Capricor will also deliver a clinical update as part of PPMD's "Novel Approaches for Combatting Duchenne" session on June 25, 2022, at 11:00 a.m. MT. The PPMD Annual Conference is the largest annual, international event focused on the latest research, clinical trials and care initiatives for DMD. Now in its 28th year, the meeting is attended by thousands of researchers, caregivers and patients looking to interact and drive change in the fight to end DMD. The conference will take place i
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyGlobeNewswire
- Edgewise gets EU orphan drug status for muscular dystrophy drug [Seeking Alpha]Seeking Alpha
- Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?PR Newswire
CAPR
Earnings
- 2/29/24 - Beat
CAPR
Analyst Actions
- 3/1/24 - HC Wainwright
CAPR
Sec Filings
- 4/24/24 - Form 4
- 4/1/24 - Form ARS
- 4/1/24 - Form DEF
- CAPR's page on the SEC website